Comparison of Ibandronate - Zoledronate Regarding Nephrotoxicity in Multiple Myeloma (COMPARE)
COMPARE: Comparison of Ibandronate - Zoledronate Regarding Nephrotoxicity in Patients With Multiple Myeloma
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Ansbach, Germany, 91522
-
Aschaffenburg, Germany, 63739
-
Augsburg, Germany, 86150
-
Berlin, Germany, 12627
-
Berlin, Germany, 10437
-
Berlin, Germany, 10707
-
Bremen, Germany, 28239
-
Duisburg, Germany, 47051
-
Duisburg, Germany, 47166
-
Erlangen, Germany, 91054
-
Essen, Germany, 45136
-
Esslingen, Germany, 73730
-
Frankfurt Am Main, Germany, 60389
-
Frankfurt Am Main, Germany, 65929
-
Greifswald, Germany, 17475
-
Göttingen, Germany, 37075
-
Güstrow, Germany, 18273
-
Gütersloh, Germany, 33332
-
Halle, Germany, 06110
-
Hamburg, Germany, 22081
-
Hamburg, Germany, 22457
-
Hamm, Germany, 59063
-
Hannover, Germany, 30625
-
Hannover, Germany, 30171
-
Herne, Germany, 44625
-
Hof, Germany, 95028
-
Jena, Germany, 07743
-
Karlsruhe, Germany, 76137
-
Kassel, Germany, 34117
-
Kassel, Germany, 34125
-
Koblenz, Germany, 56068
-
Krefeld, Germany, 47798
-
Köln, Germany, 50924
-
Köln, Germany, 50677
-
Leer, Germany, 26789
-
Leipzig, Germany, 04289
-
Ludwigshafen, Germany, 67063
-
Lübeck, Germany, 23562
-
Magedburg, Germany, 39104
-
Minden, Germany, 32427
-
Moers, Germany, 47441
-
Muenster, Germany, 48149
-
Mülheim, Germany, 45468
-
München, Germany, 80336
-
Neumünster, Germany, 24534
-
Offenbach, Germany, 63069
-
Offenburg, Germany, 77652
-
Oldenburg, Germany, 26121
-
Oldenburg, Germany, 26133
-
Stuttgart, Germany, 70199
-
Stuttgart, Germany, 70174
-
Tübingen, Germany, 72076
-
Weiden, Germany, 92637
-
Wiesbaden, Germany, 65191
-
Würzburg, Germany, 97080
-
Zwickau, Germany, 08058
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Confirmed multiple myeloma, Stage II-III as per Salmon and Durie (1975)
- Indication for biphosphonate therapy
Exclusion Criteria:
- Previous therapy with ibandronate or zoledronate within the past 12 months
- Renal insufficiency with serum creatinine >3.0 mg/dL or >265 micromoles per liter (µmol/L) or CrCl <30 mL/min
- Hypersensitivity to ibandronate, zoledronate, or other biphosphonates
- Presence of secondary malignomas, apart from basaliomas and cervical carcinoma in situ
- Severe accompanying illness with organ impairment
- Osteonecrosis of the jaw at the start of the study
- Life expectancy ≤12 months
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Ibandronate
Participants with multiple myeloma will be randomized to receive ibandronate every 4 weeks for a planned duration of 92 weeks.
|
Ibandronate will be administered via 15-minute intravenous (IV) infusion as 6 milligrams (mg) every 4 weeks for 92 weeks.
Other Names:
|
|
Active Comparator: Zoledronate
Participants with multiple myeloma will be randomized to receive zoledronate every 4 weeks for a planned duration of 92 weeks.
|
Zoledronate will be administered via 15-minute IV infusion as 4 mg every 4 weeks for 92 weeks.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percentage of Participants With Deterioration in Renal Function According to Reduction in Creatinine Clearance (CrCl) From Baseline to Week 44
Time Frame: Baseline, Week 44
|
CrCl was calculated from blood samples using the Cockcroft-Gault formula.
Relevant deterioration in renal function was defined as CrCl reduction of 30 percent (%) from Baseline or an absolute value less than or equal to (≤) 30 milliliters per minute (mL/min) at Week 44.
The last available value on/before Week 44 was used in the calculation.
The percentage of participants with deterioration in renal function at Week 44 was reported.
|
Baseline, Week 44
|
|
Percentage of Participants With Deterioration in Renal Function According to Reduction in CrCl From Baseline to Week 92
Time Frame: Baseline, Week 92
|
CrCl was calculated from blood samples using the Cockcroft-Gault formula.
Relevant deterioration in renal function was defined as CrCl reduction of 30% from Baseline or an absolute value ≤30 mL/min at Week 92.
The last available value on/before Week 92 was used in the calculation.
The percentage of participants with deterioration in renal function at Week 92 was reported.
|
Baseline, Week 92
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percentage of Participants With Skeletal-Related Events (SREs)
Time Frame: From Baseline to end of study (up to Week 96)
|
SREs were defined according to the Bondronat Summary of Product Characteristics (SmPC) to include radiotherapy to bone for treatment of fractures/impending fractures, surgery to bone for treatment of fractures, vertebral fractures, and non-vertebral fractures.
The percentage of participants with at least 1 SRE during the study was reported.
|
From Baseline to end of study (up to Week 96)
|
|
Time to First SRE
Time Frame: From Baseline to end of study (up to Week 96)
|
SREs were defined according to the Bondronat SmPC to include radiotherapy to bone for treatment of fractures/impending fractures, surgery to bone for treatment of fractures, vertebral fractures, and non-vertebral fractures.
Time to first SRE was defined as the time from first dose of study drug to the time of SRE during the study.
The median time to first SRE was estimated by Kaplan-Meier analysis and expressed in days.
|
From Baseline to end of study (up to Week 96)
|
|
Number of SREs for Each Participant
Time Frame: From Baseline to end of study (up to Week 96)
|
SREs were defined according to the Bondronat SmPC to include radiotherapy to bone for treatment of fractures/impending fractures, surgery to bone for treatment of fractures, vertebral fractures, and non-vertebral fractures.
The number of SREs was averaged across all participants, including those participants who did not experience SREs during the study.
|
From Baseline to end of study (up to Week 96)
|
|
Percentage of Participants With Osteonecrosis of Jaw
Time Frame: From Baseline to end of study (up to Week 96)
|
The percentage of participants with at least 1 event of osteonecrosis of jaw during the study was reported.
|
From Baseline to end of study (up to Week 96)
|
|
Number of Events of Osteonecrosis of Jaw for Each Participant
Time Frame: From Baseline to end of study (up to Week 96)
|
The number of events of osteonecrosis of jaw was averaged across all participants, including those participants who did not experience the event during the study.
|
From Baseline to end of study (up to Week 96)
|
|
Percentage of Participants With Zoledronate Dose Reduction
Time Frame: From Baseline to end of study (up to Week 96)
|
The percentage of participants with at least 1 zoledronate dose reduction during the study was reported.
|
From Baseline to end of study (up to Week 96)
|
|
Number of Zoledronate Dose Reductions for Each Participant
Time Frame: From Baseline to end of study (up to Week 96)
|
The number of zoledronate dose reductions was averaged across all participants, including those participants who did not have any dose reductions during the study.
|
From Baseline to end of study (up to Week 96)
|
|
Percent Change From Baseline in N-Acetyl-Beta-D-Glucosaminidase (B-NAG)
Time Frame: Baseline and Weeks 44, 92
|
The percent change in B-NAG was calculated as [Week 44 or 92 B-NAG minus Baseline B-NAG] divided by Baseline B-NAG, multiplied by 100.
For the Week 44 analysis, the last available value on/before Week 44 was used in the calculation.
For the Week 92 analysis, the last available value on/before Week 92 was used in the calculation.
|
Baseline and Weeks 44, 92
|
|
Percent Change From Baseline in Alpha (A) 1-Microglobulin
Time Frame: Baseline and Weeks 44, 92
|
The percent change in A1-microglobulin was calculated as [Week 44 or 92 A1-microglobulin minus Baseline A1-microglobulin] divided by Baseline A1-microglobulin, multiplied by 100.
For the Week 44 analysis, the last available value on/before Week 44 was used in the calculation.
For the Week 92 analysis, the last available value on/before Week 92 was used in the calculation.
|
Baseline and Weeks 44, 92
|
|
Percent Change From Baseline in Gamma-Glutamyltransferase (GGT)
Time Frame: Baseline and Weeks 44, 92
|
The percent change in GGT was calculated as [Week 44 or 92 GGT minus Baseline GGT] divided by Baseline GGT, multiplied by 100.
For the Week 44 analysis, the last available value on/before Week 44 was used in the calculation.
For the Week 92 analysis, the last available value on/before Week 92 was used in the calculation.
|
Baseline and Weeks 44, 92
|
|
Percentage of Participants With Elevation of Serum Creatinine (SCr) From Baseline
Time Frame: Baseline and Weeks 44, 92
|
Elevation in SCr was defined as an increase greater than (>) 0.5 milligrams per deciliter (mg/dL) for participants with Baseline SCr less than (<) 1.4 mg/dL, or an increase >1.0 mg/dL for participants with Baseline SCr greater than or equal to (≥) 1.4 mg/dL.
For the Week 44 analysis, the last available value on/before Week 44 was used.
For the Week 92 analysis, the last available value on/before Week 92 was used.
The percentage of participants with elevation of SCr at Weeks 44 and 92 was reported.
|
Baseline and Weeks 44, 92
|
|
Percent Change From Baseline in CrCl
Time Frame: Baseline and Weeks 44, 92
|
CrCl was calculated from blood samples using the Cockcroft-Gault formula, and was also measured by urinalysis.
The percent change in CrCl was calculated as [Week 44 or 92 CrCl minus Baseline CrCl] divided by Baseline CrCl, multiplied by 100.
For the Week 44 analysis, the last available value on/before Week 44 was used in the calculation.
For the Week 92 analysis, the last available value on/before Week 92 was used in the calculation.
|
Baseline and Weeks 44, 92
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Immunoproliferative Disorders
- Hematologic Diseases
- Hemorrhagic Disorders
- Hemostatic Disorders
- Paraproteinemias
- Blood Protein Disorders
- Multiple Myeloma
- Neoplasms, Plasma Cell
- Physiological Effects of Drugs
- Bone Density Conservation Agents
- Zoledronic Acid
- Ibandronic Acid
Other Study ID Numbers
Other Study ID Numbers
- ML18508
- 2005-003264-38 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.